Episode Details

In their Q3 2026 earnings report, Medtronic announced $9 billion in revenue, representing a significant 8.7% reported increase and the company's strongest growth in ten quarters. The Cardiovascular Portfolio emerged as a primary engine for this success, bolstered by an 80% surge in Cardiac Ablation Solutions following the expansion of pulsed field ablation technologies. Leadership highlighted several "generational growth drivers," including the FDA clearance of the Hugo surgical robot and the Stealth AXiS system, alongside strong demand for the Symplicity Spyral hypertension treatment. Despite these gains, the company managed financial headwinds from tariffs and specific product mix challenges while preparing for the planned separation of its diabetes business by late 2026. Medtronic reiterated its full-year guidance, expressing confidence that its robust innovation pipeline and strategic acquisitions will sustain high single-digit earnings growth into 2027.